NUCLEIC ACID AND CORRESPONDING PROTEIN ENTITLED 151P3D4 USEFUL IN TREATMENT AND DETECTION OF CANCER
A novel gene (designated 151P3D4) and its encoded protein, and variants thereof, are described wherein 151P3D4 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 151P3D4 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 151P3D4 gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 151P3D4 can be used in active or passive immunization.
1 . An isolated antibody or fragment thereof that specifically binds to a protein having an amino acid sequence comprising SEQ ID NO: 3 or SEQ ID NO: 5.
2 . The antibody or fragment thereof of claim 1 , which is monoclonal.
3 . The isolated antibody or fragment thereof of claim 1 , wherein the amino acid sequence comprises SEQ ID NO: 3.
4 . The isolated antibody or fragment thereof of claim 3 , wherein the amino acid sequence consists of SEQ ID NO: 3.
5 . The isolated antibody or fragment thereof of claim 1 , wherein the amino acid sequence comprises SEQ ID NO: 5.
6 . The isolated antibody or fragment thereof of claim 5 , wherein the amino acid sequence consists of SEQ ID NO: 5.
7 . The antibody or fragment thereof of claim 1 , wherein the antibody or fragment is recombinant.
8 . The antibody or fragment thereof of claim 1 , which is an Fab, F(ab′)2, Fv or Sfv fragment.
9 . The antibody or fragment thereof of claim 1 , which is a human antibody or fragment.
10 . The antibody or fragment thereof of claim 1 , wherein the antibody or fragment comprises murine antigen binding region residues and human constant region residues.
11 . The antibody or fragment thereof of claim 1 , wherein the antibody or fragment is labeled with a detectable marker.
12 . The antibody or fragment thereof of claim 1 , wherein the antibody or fragment is labeled with a cytotoxic agent.
13 . The antibody or fragment thereof of claim 12 , wherein the cytotoxic agent is selected from the group consisting of detectable markers, radioactive isotopes, chemotherapeutic agents, and toxins.
14 . The antibody or fragment thereof of claim 13 , wherein the cytotoxic agent is a radioactive isotope selected from the group consisting of 211 At, 131 I, 125 I, 90 Y, 186 Re, 188 Re, 153 Sm, 212 Bi, 32 P and radioactive isotopes of Lu.
15 . The antibody or fragment thereof of claim 13 , wherein the cytotoxic agent is a chemotherapeutic agent selected from the group consisting of taxol, actinomycin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, gelonin, and calicheamicin.
16 . The antibody or fragment thereof of claim 13 , wherein the cytotoxic agent is a toxin selected from the group consisting of diphtheria toxin, enomycin, phenomycin, Pseudomonas exotoxin (PE)A, PE40, abrin, abrin A chain, mitogellin, modeccin A chain, and alpha-sarcin.
17 . A pharmaceutical composition, comprising the antibody or fragment thereof of claim 1 and a pharmaceutically acceptable carrier.
18 . A cell that produces the antibody or fragment thereof of claim 1 .
19 . A process for producing an antibody or fragment thereof that specifically binds to a protein having an amino acid sequence comprising SEQ ID NO: 3 or SEQ ID NO: 5, comprising:
(a) culturing the cell of claim 18 under conditions sufficient for the production of the antibody or fragment thereof; and
(b) recovering the antibody or fragment thereof.